KEI Roundtable on Pathways to Scale Up Manufacturing Capacity for COVID-19 Vaccines
Channel: KEIWashDC
Date: 2021-02-19

KEI hosted a virtual roundtable to discuss pathways to scale production, increase competition and speed the delivery of COVID-19 vaccines. Experts and policymakers exchanged views on the challenges and opportunities to scale production of COVID-19 vaccines. In this dialogue, experts addressed practical issues for the transfer of know-how and technology for manufacturing.

Questions and topics that were raised include:

1. Which vaccines represent the most significant opportunities in terms of scaling manufacturing capacity and enhancing access?

06:47 - Ingrid Kromann (CEPI)
10:45 - Alain Alsahani (MSF)
16:12 - Amine Kamen (McGill University)
19:23 - Fabrizio Chiodo (Italian National Research Council)
25:32 - James Krellenstein (Prep4All)

2. What incentives, mandates and/or subsidies are useful in expanding access to vaccine manufacturing know-how and capacity?

31:11 - James Love (KEI)
39:03 - Mariângela Simão (WHO)
48:26 - Kevin McCarthy (European Commission)

3. What is currently known about global manufacturing capacity for each relevant COVID-19 vaccine, and what measures are necessary to bring a facility into good manufacturing practice compliance for production of specific vaccines and other COVID-19 health technologies?

58:23 - Edward Hammond (independent consultant)
1:04:13 - Kris Howard (NRL Enterprise Solutions)
1:11:23 - Martin Friede (WHO)
1:15:50 - Fred Abbott (Florida State University)
1:20:48 - Tertia Bailey (Manufacturing Africa Adviser for Senegal and Cote d’Ivoire)
1:25:02 - KM Gopakumar (Third World Network)

4. What is the WHO prequalification program doing regarding COVID-19 vaccines?

5. What is the WHO C-TAP doing to expand manufacturing for COVID-19 vaccines?

1:29:48 - Erika Dueñas Loayza (WHO)

6. What is the Medicines Patent Pool doing to expand manufacturing for COVID-19 vaccines?

1:35:48 - Charles Gore (MPP)

7. What are national governments doing to scale and expand vaccine manufacturing access?

01:51:07 - Arianna Schouten (KEI)

8. What mistakes were made in 2020, and what mistakes need to be avoided in 2021?

01:54:13 - Peter Singer (WHO)
01:58:42 - Mohga Kamal-Yanni (senior advisor to the People's Vaccine Alliance)
02:03:00 - Ellen ‘t Hoen (ML&P)
02:07:22 - Manuel Martin (MSF)
02:11:28 - Brook Baker (Health GAP)

Additional resources:  https://www.keionline.org/covid-19-vaccine-manufacturing-capacity

KEI is also hosting an email list to share information, resources and news on these issues. To join the public, archived list, please visit: http://lists.keionline.org/mailman/listinfo/vaccine-manufacturing_lists.keionline.org